Peripheral Blood Of The Psa, Psamrna Joint Detection For Diagnosis Of Prostate Cancer Clinical Research

Objective: To study the prostate-specific antigen and prostate specific antigen mRNA in peripheral blood samples of prostate cancer patients and to discuss their clinical implications. Methods: Samples of peripheral blood were analyzed by radio-immunity analisis and nested reverse transcription-polymerase chain reaction based assay to identify PSA,PSAmRNA expression. Results:â‘ The serum levels between prostate cancer group and benign prostatic hyperplasia group have statistic differences(P<0.05).â‘¡The serum levels of prostate cancer patients has no statistic differences in difference age groups(P>0.05),but has statistic differences in difference clinical groups and Gleason groups (P<0.05).â‘¢No PSA mRNA expression has been detected in all the 20 BPH patients.Whereas, positive expression has been observed in 19 of the prostate cancer patients(67.86%).â‘£The expression of PSAmRNA has no statistic differences in difference age groups and Gleason groups(P>0.05),but has statistic differences in difference clinical groups and hormonal therapy groups ( P<0.05 ) .Conclusion: Combined measurement of PSA,PSAmRNA in peripheral blood of prostate cancer patients is a simple measurement which can early diagnose prostate cancer, judge the transformation , arrange the clinical group, foresee the recrudescence and evaluate therapy effect.